Kainos

Muenster Milling Names Jim Holdrieth as President and CEO

Retrieved on: 
Wednesday, November 15, 2023
Veterinary, Packaging, Pets, Chemicals, Plastics, Manufacturing, Food, Beverage, Health, Consumer, Retail, Growth, FFP, Sport, Food safety, Bottled water, Convenience food, Kainos

Muenster Milling Company (“Muenster”), a manufacturer of freeze-dried and extruded pet food sold under its brand as well as for other well-known pet food brands, today announced the appointment of Jim Holdrieth as President and CEO.

Key Points: 
  • Muenster Milling Company (“Muenster”), a manufacturer of freeze-dried and extruded pet food sold under its brand as well as for other well-known pet food brands, today announced the appointment of Jim Holdrieth as President and CEO.
  • Most recently, Mr. Holdrieth served as CEO of Florida Food Products (“FFP”), a formulator and manufacturer of natural and clean label ingredients for the food, beverage, sports and pet nutrition industries.
  • Muenster is a portfolio company of Kainos Capital, a consumer-focused private equity firm that invests in strategically relevant companies in the food, pet, consumer products and services sectors.
  • Fourth-generation Muenster family owners Mitch and Chad Felderhoff said, "We could not be happier to welcome Jim Holdrieth into the Muenster family.

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Nausea, Cough, Sickle cell disease, Splenomegaly, United Kingdom, Constipation, United Arab Emirates, Private Securities Litigation Reform Act, Incidence, Indigestion, Gulf Cooperation Council, Security (finance), Research, Annual report, Pain, Net, Cancer, Emma Walmsley, Marketing, Patient, Abdominal pain, Kingdom, COVID-19, Company, Chest pain, IRAK4, Ministry, Diverticulosis, Safety, Loss, Headache, Operating cost, Back pain, Expense, Extremities, Time, Food, Adult, Kainos, OTCQX, Pharmaceutical industry, Income, Glutamine, Health, Q2

TORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • TORRANCE, Calif., Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
  • Net revenues in Q2 2022 increased by $1.1 million, or nearly 33%, from Q1 2022 net revenues of $3.2 million.
  • Loss from operations in Q2 2022 decreased by $1.6 million, or 53.1%, from $3.1 million in Q1 2022 as a result of the increase in net revenues in Q2.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights

Retrieved on: 
Friday, November 12, 2021
Education, Constipation, Chest pain, Security (finance), National Health Regulatory Authority, Food, Extremities, Lymphoma, COVID-19, Cancer, Splenomegaly, Pain, MYD88, Review, Drug, Expense, Safety, Food and Drug Administration, Kainos, Trial of the century, Research, Diverticulosis, Travel, Headache, U.S. Securities and Exchange Commission, Sickle cell disease, Time, Marketing, Gulf Cooperation Council, Patient, United Arab Emirates, FDA, Adult, SCD, Private Securities Litigation Reform Act, Ministry, NHRA, Mutation, Kingdom, Back pain, Application, Prescription, SEC, Cough, Leukemia, Nausea, Telehealth, OTCQX, Annual report, Partnership, Period, Incidence, Article 13, Indigestion, Emma Walmsley, Abdominal pain, Health insurance, Pharmaceutical industry, Animal, Cryptocurrency

TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months ended September 30, 2021.

Key Points: 
  • TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the quarter and nine months ended September 30, 2021.
  • Asembia will provide a single point of contact for benefits investigation, financial and co-pay assistance, as well as patient and provider education.
  • Net revenues declined 6% compared to the second quarter of 2021 primarily due to lower bulk orders in the third quarter than in the second quarter.
  • Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Securiti Secures Workday as Strategic Investor and Partner

Retrieved on: 
Wednesday, May 26, 2021
Software, Technology, Data management, Security, Computer companies, Workday, Inc., Computing, Companies, Performance management, Adaptive Insights, Kainos, Enterprise software, Securiti, Workday Ventures, SECURITI, WORKDAY VENTURES

Securiti , the leader in AI-powered data privacy and security, today announced it has received a strategic investment from Workday Ventures and will join the Workday Software Partner Program.

Key Points: 
  • Securiti , the leader in AI-powered data privacy and security, today announced it has received a strategic investment from Workday Ventures and will join the Workday Software Partner Program.
  • As a Workday Ventures software partner, Securiti will be able to create an integration with Workday to address key enterprise requirements for data privacy, security, and compliance.
  • Securiti and Workday share a joint commitment to deliver innovative solutions that help our customers better manage their data, said Betsy Bland, vice president and managing director of Workday Ventures.
  • Workday Ventures is the strategic investment arm of Workday, Inc., focused on accelerating the growth of emerging enterprise software companies that enhance the Workday customer experience and are complementary to Workday products and services.

Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug

Retrieved on: 
Tuesday, March 2, 2021
Kainos, Emmaus, Pharmaceutical industry

In a related development, the companies also entered into a letter of intent regarding possible future joint development of small molecule therapeutics and other pharmaceutical assets.

Key Points: 
  • In a related development, the companies also entered into a letter of intent regarding possible future joint development of small molecule therapeutics and other pharmaceutical assets.
  • Kainos will receive $500,000 in cash and $500,000 in shares of Emmaus common stock in consideration for entering into the agreement.
  • "Emmaus is pleased to partner with Kainos to further advance the research and development activity of KM10544," said Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.
  • Kainos receives specialized counsel on product selection, evaluation and external licensing deals from advisory boards and business development consultants who have skills and significant experience in global drug development.

Nutrisystem Names Stephen Mikulak As New President

Retrieved on: 
Monday, February 22, 2021
Nutrisystem, Upper Dublin Township, Montgomery County, Pennsylvania, Business, Articles, Companies, Mikulak, Kainos, Brand, Marketing

FORT WASHINGTON, Penn., Feb. 22, 2021 /PRNewswire/ -- Nutrisystem, the preeminent direct-to-consumer nutrition and weight management brand, today announced that Stephen Mikulak has been named the company's new President, effective immediately.

Key Points: 
  • FORT WASHINGTON, Penn., Feb. 22, 2021 /PRNewswire/ -- Nutrisystem, the preeminent direct-to-consumer nutrition and weight management brand, today announced that Stephen Mikulak has been named the company's new President, effective immediately.
  • Mr. Mikulak was previously Nutrisystem's Chief Revenue Officer and has been a leader in the company's marketing organization since 2014.
  • Bob Sperry, a Partner at Kainos Capital, a private equity firm specializing in food and consumer businesses that acquired Nutrisystem in Decemberof last year , said, "We are very excited to promote Steve Mikulak to serve as President of Nutrisystem.
  • Mr. Mikulak said, "I am honored to be appointed Nutrisystem's new President.

Kainos Capital Announces Addition of Alex Stanek to Operations Team

Retrieved on: 
Monday, January 11, 2021
Kainos, Supply chain

Andrew Rosen, Managing Partner of Kainos, said: "We are excited to officially welcome Alex to the Kainos team.

Key Points: 
  • Andrew Rosen, Managing Partner of Kainos, said: "We are excited to officially welcome Alex to the Kainos team.
  • Alex will work directly with Kim Homa, our Director of Supply Chain and long-time member of the Kainos Operations Team.
  • We look forward to her joining the Kainos Operations Team and believe she will be a great addition to the Kainos culture."
  • Kainos Capital is a middle market private equity firm with an exclusive focus on the food and consumer products sectors .

Kainos Capital Announces New Senior Associates

Retrieved on: 
Wednesday, August 5, 2020
Kainos, Private equity firm

DALLAS, Aug. 5, 2020 /PRNewswire/ --Kainos Capital ("Kainos"), a food and consumer-focused private equity firm, today announced that Catherine Anne Prideaux, Christina Wang and John Hudgens were promoted from Associate to Senior Associate, effective August 1.

Key Points: 
  • DALLAS, Aug. 5, 2020 /PRNewswire/ --Kainos Capital ("Kainos"), a food and consumer-focused private equity firm, today announced that Catherine Anne Prideaux, Christina Wang and John Hudgens were promoted from Associate to Senior Associate, effective August 1.
  • Andrew Rosen, Managing Partner, said "The professionals on the Kainos investment team are critical to the firm's ability to drive growth and value across the Kainos portfolio.
  • Since joining the firm in 2018, Catherine Anne, Christina and John have demonstrated exceptional work ethic and technical development as private equity professionals.
  • Kainos Capital is a middle market private equity firm with an exclusive focus on the food and consumer products sectors.

Kainos Capital Portfolio Company Olde Thompson Acquires Gel Spice, Expanding National Footprint

Retrieved on: 
Wednesday, July 22, 2020
Finance, Money, Economy, Kainos, Private equity

Olde Thompson is a portfolio company of Kainos Capital, a private equity firm focused exclusively on the food and consumer industry.

Key Points: 
  • Olde Thompson is a portfolio company of Kainos Capital, a private equity firm focused exclusively on the food and consumer industry.
  • The Kainos Capital team has invested over $2 billion of equity in 73 investments with a total value over $10 billion.
  • "Olde Thompson is thrilled to partner with Gel to expand our platform," says Jeff Shumway, CEO of Olde Thompson.
  • David Sugarman, CEO of Gel, who has become Co-CEO of Olde Thompson, shared, "The Engel family, which will continue to be a shareholder, and I are thrilled to be part of Olde Thompson.

Kainos Joins Forces With IntuitiveTEK; Deepens Existing Expertise in Adaptive Insights Business Planning Cloud

Retrieved on: 
Monday, March 2, 2020
Adaptive Insights, Performance management, Kainos, Digital transformation, Articles, Information and communications technology, Digital technology

IntuitiveTEKis a leading North American partner to Adaptive Insights, a Workday company powering a new generation of business planning.

Key Points: 
  • IntuitiveTEKis a leading North American partner to Adaptive Insights, a Workday company powering a new generation of business planning.
  • Following the purchases of Formulate and Implexa at the end of 2019, which extended Kainos' Adaptive Insights capabilities in the UK and European markets, the acquisition of IntuitiveTEK makes Kainos one of the largest Adaptive Insights practices globally.
  • This acquisition reflects Kainos' ambition to change the way the world lives and works by helping customers to drive business planning and digital transformation by leveraging Workday's leading suite of applications in finance, HR and business planning.
  • Brian Storrs, Founder and President, IntuitiveTEK, added, "From the start, we saw the incredible benefits of the Adaptive Insights Business Planning Cloud and as Adaptive Insights has grown, so have we.